Jon — built for our conversation about messaging as you move toward the clinic.
Your Sachs question about “doing no harm” if we fail to preserve tissue for normal metabolism could be the lead story. Right now, mechanism leads. Story follows.
Your question at Sachs "Are we doing no harm if we fail to preserve the tissue needed for normal metabolism?"
Developing mitochondrial-targeted small molecule therapeutics for superior quality weight loss in obesity
Because losing weight shouldn't mean losing muscle, bone, or metabolic health. We're building the medicine that asks—and answers—that question.
ADA · EASD · ECO 2025GLP-1s own “weight loss.” You own “weight loss without losing what matters.” That second story is differentiated—and it’s the one you voiced on the panel. The gap is consistency: investor decks, homepage, LinkedIn. Align those, and the narrative in the boardroom becomes the narrative in shipped assets.
We built this page as a proof of concept. On a discovery call we’d apply this lens to your investor and BD funnel and come back with a 90-day blueprint.
We’ll map your narrative across touchpoints, sharpen messaging, and come back with a 90-day blueprint—one goal, three key results.
Book a 45-minute discoveryNo pitch—we’ll apply this lens live and decide together if there’s a fit.